MedWatch

Leo Pharma will not use acquisition option after candidate disappoints in phase III trial

Leo Pharma partner Pellepharm's drug patidegib has not generated sufficiently convincing phase III data for the dermatology group to utilize its acquisition option and take over the candidate – and the company.

Photo: Leo Pharma / PR

A Danish billion-kroner acquisition of Californian biotech company Pellepharm will not be happening.

Leo Pharma confirms to MedWatch that the company has decided not to utilize the acquisition option it secured in 2018, which would have allowed it to acquire its US partner Pellepharm. The agreement concerned a collaboration to develop patidegib, a treatment for the rare skin condition Gorlin syndrome.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs